Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Free Cash Flow (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Free Cash Flow for 4 consecutive years, with -$60.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 191.28% to -$60.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.3 million through Dec 2025, up 40.45% year-over-year, with the annual reading at -$33.3 million for FY2025, 40.45% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$60.2 million at Spruce Biosciences, down from $48.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was $48.5 million in Q3 2025, with the low at -$60.2 million in Q4 2025.
  • Average Free Cash Flow over 4 years is -$10.3 million, with a median of -$11.5 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 657.25% in 2024, then soared 625.37% in 2025.
  • Over 4 years, Free Cash Flow stood at -$11.7 million in 2022, then increased by 4.51% to -$11.2 million in 2023, then tumbled by 84.47% to -$20.7 million in 2024, then plummeted by 191.28% to -$60.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$60.2 million, $48.5 million, and -$8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.